Biopharmaceutical company Innovent Biologics Inc (HKEX:01801) announced Monday that it has entered into a collaboration agreement with Shenogen Pharma Group Ltd for advanced cancer.
This collaboration will evaluate the combination therapy of Innovent's Tyvyt (generic name: sintilimab injection)with Shenogen's SNG1005, in patients with advanced cancer.
Tyvyt (sintilimab Injection) is the anti-PD-1 inhibitor co-developed by Innovent and Eli Lilly and Company (Lilly). Tyvyt (sintilimab injection) is a type of immunoglobulin G4 monoclonal antibody, which binds to PD-1 molecules on the surface of T-cells, blocks the PD-1/ PD-1 Ligand-1 (PD-L1) pathway and reactivates T-cells to kill cancer cells. Tyvyt (sintilimab injection) is the only PD-1 antibody in China branded by both a local biopharmaceutical company and a global pharmaceutical company.
SNG1005 is a conjugate of angiopep-2 and paclitaxel that Shenogen licensed from overseas. SNG1005 binds to the low-density lipoprotein receptor-related protein 1 (LRP1), which is abundantly expressed on the Blood Brain Barrier (BBB), which facilitates efficient transcytosis movement of paclitaxel across the BBB.
In addition, Shenogen has the full development and commercialization rights for SNG1005 in Greater China. The Investigational New Drug (IND) application of Phase II/III clinical trial for breast cancer carcinoma brain metastases (BCBS) in China has been approved by the National Medical Products Administration (NMPA).
The combined therapy of immune check point inhibitors and anti-tumor therapeutics has become the standard approach for the development of anti-tumor treatments. Innovent will explore the potential efficacy of anti-PD-1 inhibitor in combination with SNG1005 in various cancers, concluded Dr Kun Meng, Chairman of Shenogen.
Apotex launches Teriparatide Injection in US
Teva Pharmaceuticals secures FDA approval for generic Forteo (teriparatide injection)
Upsher-Smith Laboratories introduces Pitavastatin Tablets
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Sanofi and Teva collaborate on innovative IBD treatment
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling